Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Zynex ( (ZYXI) ) has shared an update.
On December 15, 2025, Zynex, Inc. filed for Chapter 11 bankruptcy in the Southern District of Texas, initiating a court-supervised financial restructuring supported by a $22.3 million DIP Facility from its lenders. The restructuring plan includes a competitive sale process to sell all or substantially all of the company’s assets or equity interests, with operations continuing as usual to ensure no impact on patients, customers, or employees. This move is aimed at positioning Zynex for long-term success, although it poses significant risks to equity holders who may experience substantial losses.
The most recent analyst rating on (ZYXI) stock is a Sell with a $0.84 price target. To see the full list of analyst forecasts on Zynex stock, see the ZYXI Stock Forecast page.
Spark’s Take on ZYXI Stock
According to Spark, TipRanks’ AI Analyst, ZYXI is a Underperform.
Zynex’s overall stock score is significantly impacted by its poor financial performance, with declining revenues, high leverage, and negative equity. The technical analysis further indicates a bearish trend, while the valuation is unattractive due to a negative P/E ratio. The earnings call and corporate events highlight ongoing financial and operational challenges, despite strategic initiatives.
To see Spark’s full report on ZYXI stock, click here.
More about Zynex
Zynex, Inc., founded in 1996, is a medical technology company that specializes in the development, manufacture, and sale of non-invasive medical devices for pain management and rehabilitation.
Average Trading Volume: 4,786,511
Technical Sentiment Signal: Sell
Current Market Cap: $22.49M
Learn more about ZYXI stock on TipRanks’ Stock Analysis page.